Physician profile
Peter A Lechman
NPI 1972544328
$3,958.72
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,509 · 2020: $170 · 2021: $1,263 · 2022: $17.62.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $2,136.51 | 2019-2022 | |
| Pierre Fabre Pharmaceuticals, INC. | $1,050.00 | 2021 | |
| Glaxosmithkline, LLC. | $229.50 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $138.32 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $115.13 | 2019-2020 | |
| Cranial Technologies, INC | $79.24 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $75.29 | 2019-2021 | |
| Kaleo, INC. | $72.79 | 2019-2021 | |
| Shire North American Group INC | $31.12 | 2019 | |
| Sanofi Pasteur INC. | $17.69 | 2019 | |
| Neos Therapeutics, LP | $13.13 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Lechman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.